It is
estimated that hearing thresholds are elevated in 10-20% of those receiving aminoglycoside
antibiotics and as much as 80% in cisplatin-treated patients [3, 6]. However, because of their
cost and/or robust effectiveness, these drugs continue to be used while their ototoxic effects
often limit drug-dosing paradigms.